Ftse Mib
34.460,52
-0,41%
DAX
18.680,20
-0,25%
S&P 500
5.307,01
-0,27%
NASDAQ
16.801,54
-0,18%
Bitcoin
69.425,99
0,47%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Adverum Biotechnologies Inc (ADVM) Adverum Biotechnologies Inc (ADVM) Notizie

ADVM

Adverum Biotechnologies (ADVM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ADVM
DataOraFonteTitoloSimboloCompagnia
09/05/202422:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADVMAdverum Biotechnologies Inc
09/05/202422:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
09/05/202422:05GlobeNewswire Inc.Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline HighlightsNASDAQ:ADVMAdverum Biotechnologies Inc
03/05/202414:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in Upcoming May Investor ConferencesNASDAQ:ADVMAdverum Biotechnologies Inc
25/04/202422:05GlobeNewswire Inc.Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingNASDAQ:ADVMAdverum Biotechnologies Inc
18/03/202421:05GlobeNewswire Inc.Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesNASDAQ:ADVMAdverum Biotechnologies Inc
04/03/202422:40Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ADVMAdverum Biotechnologies Inc
28/02/202422:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
22/02/202421:47Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADVMAdverum Biotechnologies Inc
21/02/202421:39Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ADVMAdverum Biotechnologies Inc
15/02/202402:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ADVMAdverum Biotechnologies Inc
14/02/202422:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
12/02/202414:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
08/02/202413:00GlobeNewswire Inc.Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDNASDAQ:ADVMAdverum Biotechnologies Inc
05/02/202413:45GlobeNewswire Inc.Adverum Biotechnologies Announces $127.5 Million Private Placement FinancingNASDAQ:ADVMAdverum Biotechnologies Inc
01/02/202423:30GlobeNewswire Inc.Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024NASDAQ:ADVMAdverum Biotechnologies Inc
29/01/202414:00GlobeNewswire Inc.Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific OfficerNASDAQ:ADVMAdverum Biotechnologies Inc
07/12/202322:05GlobeNewswire Inc.Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula SocietyNASDAQ:ADVMAdverum Biotechnologies Inc
04/12/202322:09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ADVMAdverum Biotechnologies Inc
28/11/202322:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
09/11/202322:05GlobeNewswire Inc.Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline HighlightsNASDAQ:ADVMAdverum Biotechnologies Inc
07/11/202301:52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
06/11/202314:00GlobeNewswire Inc.Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of DirectorsNASDAQ:ADVMAdverum Biotechnologies Inc
04/11/202322:54GlobeNewswire Inc.Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023NASDAQ:ADVMAdverum Biotechnologies Inc
26/09/202322:05GlobeNewswire Inc.Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 TrialNASDAQ:ADVMAdverum Biotechnologies Inc
21/09/202322:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in Upcoming Investor ConferencesNASDAQ:ADVMAdverum Biotechnologies Inc
05/09/202322:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
21/08/202322:05GlobeNewswire Inc.Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology OfficerNASDAQ:ADVMAdverum Biotechnologies Inc
14/08/202314:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
10/08/202322:05GlobeNewswire Inc.Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial ResultsNASDAQ:ADVMAdverum Biotechnologies Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ADVM

La tua Cronologia

USOTC
PDRDF
Pernod Ricard (PK)
EU
CQYAD
COM Agglo ST Quentin Yve...
BIT
P1UV35
NLBNPIT1UV35 20351221 6....
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network